R. Yarden

发表

BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions

R. Yarden, M. Papa, 2006, Molecular Cancer Therapeutics.

BRCA1 interacts with components of the histone deacetylase complex.

R. Yarden, L. Brody, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells

R. Yarden, U. Dianzani, R. Cavalli, 2018, Oncotarget.

Identification of proteins that interact with BRCA1 by Far‐Western library screening

R. Yarden, L. Brody, 2001, Journal of cellular biochemistry.

Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit

R. Yarden, J. Marshall, B. Weinberg, 2020, Colorectal Cancer.

Vaccination against breast cancer--studies in an animal model.

R. Yarden, N. Smorodinsky, D. Wreschner, 1994, Advances in experimental medicine and biology.

Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)

R. Yarden, M. Perelman, I. Barshack, 2014, memo - Magazine of European Medical Oncology.

Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair

Y. Pommier, R. Yarden, C. Albanese, 2016, Oncotarget.

Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogramed primary prostate cancer cells.

R. Yarden, Richard J Lee, C. Albanese, 2014, Oncotarget.

Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.

R. Yarden, M. Papa, A. Yosepovich, 2007, Cancer letters.

Insulin-like growth factor-I controls BRCA1 gene expression through activation of transcription factor Sp1.

R. Yarden, M. Papa, H. Werner, 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage

Lawrence C. Brody, R. Yarden, K. Cowan, 2002, Nature Genetics.

Using consistent terms in precision medicine to eliminate patient confusion.

R. Yarden, S. Friedman, G. Hooker, 2020 .

Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth *

R. Yarden, S. Chrysogelos, M. Wilson, 2001, Journal of cellular biochemistry. Supplement.

The Role of Estrogen in the Regulation of EGFR Expression

Melissa A. Wilson, R. Yarden, S. Chrysogelos, 1997 .

Haplotype structure and selection of the MDM2 oncogene in humans

Doron Lancet, John Sninsky, G. Atwal, 2007, Proceedings of the National Academy of Sciences.

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent

R. Yarden, M. Papa, E. Friedman, 2008, Breast Cancer Research and Treatment.

Mechanisms of EGF receptor regulation in breast cancer cells

R. Yarden, S. Chrysogelos, Ronit I. Yarden, 2004, Breast Cancer Research and Treatment.

Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells.

R. Yarden, D. El-Ashry, S. Chrysogelos, 1996, Endocrinology.

Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression.

W. Bamlet, R. Yarden, A. Klein, 2016, Human molecular genetics.

BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation

R. Yarden, M. Papa, A. Pietraszkiewicz, 2013, Oncogene.

Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1.

Adrian V. Lee, R. Yarden, M. Papa, 2006, The Journal of endocrinology.

Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells

R. Yarden, M. Papa, S. Byers, 2014, Oncotarget.

Cooperation between BRCA 1 and vitamin D is critical for histone acetylation of the p 21 waf 1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells

R. Yarden, M. Papa, S. Byers, 2014 .

Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model

R. Yarden, M. Pines, Michael D. Johnson, 2015, Cancer biology & therapy.

Single‐nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish‐Ashkenazi descent

R. Yarden, M. Papa, E. Friedman, 2010, Molecular carcinogenesis.

Abstract 3347: Young onset colorectal cancer patients are diagnosed with advanced disease after multiple misdiagnoses

R. Yarden, K. L. Newcomer, Colorectal CancerAlliance, 2019, Science and Health Policy.

Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells

R. Yarden, Y. Kapulnik, C. Prandi, 2012, Breast Cancer Research and Treatment.

Cooperation between BRCA1 and vitamin D is critical for histone acetylation of the p21waf1 promoter and for growth inhibition of breast cancer cells and cancer stem-like cells

R. Yarden, M. Papa, S. Byers, 2014, Oncotarget.

BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest.

R. Yarden, M. Papa, S. Shabbeer, 2012, The international journal of biochemistry & cell biology.